AAVXF (Abivax) Beta: 0.2742 (As of Jun. 25, 2026)


AAVXF Abivax SA AAVXF
25 GF Score
Price $80.03
! 1 Warning Sign
View Full Analysis

What is Abivax Beta?

Abivax AAVXF -20.96% 25 Beta is 0.2742 as of Jun. 25, 2026. GuruFocus rates AAVXF with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Abivax's Beta is 0.2742.


Abivax  (OTCPK:AAVXF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Abivax Beta Related Terms


Abivax Beta Historical Data

* Premium members only.

The historical data trend for Abivax's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Beta Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.76 0.37 0.48 0.32

Abivax Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 -0.57 0.32 0.32 1.16

AAVXF vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Abivax's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abivax Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's Beta distribution charts can be found below:

* The bar in red indicates where Abivax's Beta falls into.


AAVXF
25GF Score
Abivax SA AAVXF
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2742 mean?
Abivax (AAVXF) has a Beta of 0.2742 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Abivax and its competitors.
Is Abivax's Beta too high?
Abivax's current Beta is 0.2742. Overall, Abivax has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's Beta compare to VRTX and REGN?
Abivax's Beta of 0.2742 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Abivax and its competitors. Abivax's current Beta is 0.2742. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (AAVXF) has a current Beta of 0.2742. The current Beta is 0.2742. Abivax's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Abivax (AAVXF), the current Beta is 0.2742 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
25GF Score

Get the complete analysis for AAVXF

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.03
Price